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ABSTRACT:
One-hundred-fifty-three biliary cancers, including 70 intrahepatic 
cholangiocarcinomas (ICC), 57 extrahepatic cholangiocarcinomas (ECC) and 26 
gallbladder carcinomas (GBC) were assessed for mutations in 56 genes using 
multigene next-generation sequencing. Expression of EGFR and mTOR pathway genes 
was investigated by immunohistochemistry. At least one mutated gene was observed 
in 118/153 (77%) cancers. The genes most frequently involved were KRAS (28%), 
TP53 (18%), ARID1A (12%), IDH1/2 (9%), PBRM1 (9%), BAP1 (7%), and PIK3CA 
(7%). IDH1/2 (p=0.0005) and BAP1 (p=0.0097) mutations were characteristic of 
ICC, while KRAS (p=0.0019) and TP53 (p=0.0019) were more frequent in ECC and 
GBC. Multivariate analysis identified tumour stage and TP53 mutations as independent 
predictors of survival. Alterations in chromatin remodeling genes (ARID1A, BAP1, 
PBRM1, SMARCB1) were seen in 31% of cases. Potentially actionable mutations were 
seen in 104/153 (68%) cancers: i) KRAS/NRAS/BRAF mutations were found in 34% 
of cancers; ii) mTOR pathway activation was documented by immunohistochemistry 
in 51% of cases and by mutations in mTOR pathway genes in 19% of cancers; iii) 
TGF-ß/Smad signaling was altered in 10.5% cancers; iv) mutations in tyrosine kinase 
receptors were found in 9% cases. Our study identified molecular subgroups of 
cholangiocarcinomas that can be explored for specific drug targeting in clinical trials. 
INTRODUCTION
Cholangiocarcinoma is a phenotypical and clinical 
heterogeneous collection of biliary tract malignancies, 
classified according to the World Health Organization 
(WHO) as intrahepatic (ICC) or extrahepatic 
cholangiocarcinomas (ECC) [1, 2]. The former arise in 
the substance of the liver, the latter in large extrahepatic 
ducts, i.e. hepatic ducts and common bile duct. 
Gallbladder carcinomas (GBC) also have biliary epithelial 
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differentiation. Clinically, both cholangiocarcinomas and 
GBC have very poor prognosis. Surgical resection is 
the only potentially curative therapy, but most cases are 
inoperable [3-7]. In contrast to other solid tumours, no 
effective molecular targeted agent has been approved for 
biliary tract cancers, and patients have limited access to 
clinical trials [8-11].
Previous studies on molecular alterations in biliary 
tract cancers have focused on selected genes, including 
those altered in pancreatic adenocarcinoma (KRAS, TP53, 
CDKN2A and SMAD4) [12]. Mutations in PIK3CA, 
PTEN, AKT1, IDH1 and IDH2 have been reported in this 
class of tumours [13-20]. However, the prevalence of these 
alterations varies widely among studies. Two recent whole 
exome-sequencing studies of ICC revealed a key role for 
chromatin remodeling genes BAP1, ARID1A and PBRM1 
in the development of these tumours [13, 21].
The validation of whole exome studies by 
sequencing analysis of hotspot mutations in larger and 
characterized series has been a fruitful approach in 
identifying potential targets for personalized therapy for 
several malignancies [22]. Next-generation sequencing 
(NGS) has been recently introduced and is the most 
sensitive approach to simultaneously characterize multiple 
genes starting from a limited amount of DNA, also DNA 
derived from formalin-fixed paraffin-embedded (FFPE) 
samples [13, 23-25].
In the present study, we assayed the mutational status 
of 56 cancer-related genes in 153 biliary tract cancers, 
using a targeted next-generation sequencing methodology, 
with the aim of identifying molecular subgroups driving 
the development of personalized therapy approaches for 
patients affected by these neoplasms.
RESULTS
Clinico-pathological characteristics of the series
Patients’ demographic and clinico-pathological data 
are summarized in Table 1. Mean tumour size was 4.8±3.4 
cm (median=6.5; range=0.5-20.0), and was significantly 
higher in ICC than ECC and GBC (p=9.77 E-12). 
Synchronous multinodular lesions were found in 31 cases 
(20.3%). Tumour grading was G1 in 20, G2 in 94, and G3 
in 38 cases, while the remaining case was undifferentiated.
Biliary intraepithelial neoplasia (BilIN) was 
present in 49/153 cases (32.0%), and its prevalence was 
significantly higher in ECC and GBC compared to ICC 
(ICC=15.7%; ECC=42.1%; GBC=53.8%; p=0.0002). 
Vascular and perineural invasion were present in 107 
(69.9%) and 93 (60.8%) cases, respectively. Perineural 
invasion showed a significantly lower prevalence in 
ICC than ECC and GBC (ICC=44.3%; ECC=77.2%; 
GBC=69.2%; p=0.0005). Hepatitis virus infection 
(HBV and/or HCV) and cirrhosis prevalence were 
significantly higher in ICC patients (p=0.041 and p=0.005, 
respectively).
The pathologic stage of the 153 neoplasms was 
Stage I in 20, II in 51, III in 43, and IV in 39. ICC 
presented with more advanced stages at surgery compared 
to ECC and GBC (Table 1; p=0.034).
Next-generation sequencing of 56 genes dissects 
cholangiocarcinoma molecular heterogeneity
DNA from all samples was successfully amplified 
in multiplex PCR for the 56 genes and an adequate library 
for deep sequencing was obtained. The mean read length 
was 78 base pairs and a mean coverage of 1800x was 
achieved, with 87.1% target bases covered more than 
100x. A minimum coverage of 20x was obtained in all 
cases.
At least one mutation was observed in 118/153 
(77.1%) samples (Table 2, Figure 1); 60 cases (39.2%) 
showed concurrent mutations in different genes; 35 
(22.9%) tumours showed no alterations in the 56 genes 
assayed. The most commonly mutated genes in the whole 
series were KRAS (28.1%), TP53 (18.3%), ARID1A 
(11.8%), IDH1/IDH2 (9.2%), PBRM1 (9.2%), BAP1 
(7.2%), and PIK3CA (7.2%). Mutations in BRAF, KRAS, 
and TP53 were all confirmed at Sanger sequencing (Figure 
2).
Mutations were differently distributed across the 
different tumour subtypes: IDH1/IDH2 (p=0.0005) were 
restricted to ICC and BAP1 mutations were all found in 
ICC (p=0.0097) with the exception of one GBC, while 
KRAS (p=0.0019) and TP53 (p=0.0019) were more 
represented in ECC and GBC, respectively (Table 2). 
ICC were characterized by a high prevalence 
of IDH1/IDH2 mutations (20.0%) and the significant 
involvement of chromatin remodeling genes PBRM1 
(14.3%), BAP1 (14.3%) and ARID1A (11.4%) (Figure 
3), as described[32, 33]. BAP1 and IDH1 were mutually 
exclusive, whereas mutations in IDH2 were always 
associated to BAP1 mutations (3/3 cases). Eleven (15.7%) 
ICC had mutations in at least one of mTOR pathway 
genes: AKT1 (2.8%), PIK3CA (5.7%), PIK3C2A (7.1%), 
PIK3C2G (4.3%), and PTEN (1.4%). Mutations in tyrosine 
kinase receptors were uncommon, with the exception of 
TGFRB2 (4.3%). Of interest, most NRAS (5 of 6) and all 
BRAF (3 of 3) mutations clustered in ICC tumour subtype 
and were mutually exclusive with KRAS (15.7%). TP53 
was mutated in 6 cases (8.6%). Low prevalence mutations 
were found in APC, CDKN2A, ERBB4, FBXW7, FGFR3, 
KDR/VEGFR2, SMAD4, and STK11.
In ECC, KRAS was the most commonly mutated 
gene (47.4%), with codons 12, 13, 61 and 146 affected; 
one mutation was observed in NRAS, and none in BRAF. 
TP53 was the second most mutated gene (17.5%). 
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Table 1: Clinico-pathological features of 153 biliary carcinomas.
Total
(n=153)
ICC
(n=70)
ECC
(n=57)
GBC
(n=26) P-value*
Sex 59F 94M 28F 42M 20F 37M 11F 15M 0.776
Age 65.4±10.8 64.8±11.6 64.2±10.8 69.6±8.0 0.118
Dimension (cm) 4.8±3.4 6.6±3.7 2.6±1.3 3.3±1.4 9.77 E-12
Multiple nodes 31(20.3%)
28
(40.0%)
3
(5.3%) - 2.84 E-6
Grade 1 20(13.1%)
7
(10.0%)
8
(14.0%)
5
(19.2%)
0.630
2 94(61.4%)
45
(64.3%)
36
(63.2%)
13
(50.0%)
3 38(24.8%)
18
(25.7%)
12
(21.0%)
8
(30.7%)
4 1(0.6%)
0
(0.0%)
1
(1.8%)
0
(0.0%)
Presence of 
BiIIN
49
(32.0%)
11
(15.7%)
24
(42.1%)
14
(53.8%) 0.0002
Vascular 
invasion
107
(70.0%)
51
(72.9%)
38
(66.7%)
18
(69.2%) 0.773
Perineural 
invasion
93
(60.8%)
31
(44.3%)
44
(77.2%)
18
(69.2%) 0.0005
Radicality of 
resection
R0 110 (71.9%)
56
(80.0%)
33
(57.9%)
19
(73.1%)
0.068
R1 43 (28.1%)
14
(20.0%)
24
(42.1%)
7
(26.9%)
HBV/HCV 
infection
22
(14.4%)
17
(24.3%)
3
(5.3%)
2
(7.7%) 0.041
Cirrhosis 13(8.5%)
10
(14.3%)
3
(5.3%)
0
(0.0%) 0.005
Stage I 20(13.1%)
12
(17.1%)
5
(8.8%)
3
(11.5%)
0.034
II 51(33.3%)
21
(30.0%)
22
(38.6%)
8
(30.7%)
III 43(28.1%)
12
(17.1%)
20
(35.1%)
11
(42.3%)
IV 39(25.5%)
25
(35.8%)
10
(17.5%)
4
(15.4%)
Note: ICC, intrahepatic cholangiocarcinoma; ECC, extrahepatic cholangio-carcinoma; GBC, gallbladder 
carcinoma; BiIIN, biliary intraepithelial neoplasia
Fisher’s exact test for categorical data, Kruskal-Wallis test for continuous variables.
# Chi-squared test with Monte Carlo simulation (2000 replicates).
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Table 2: Mutational status of 153 biliary tract carcinomas.
Gene Total
Type of mutation ICC ECC GBC 
P-value*
M N Fs D S (n= 70) (n= 57) (n= 26)
AKT1 2 2 2 -
ALK 1(0.7%) 1 1(1.7%) -
APC 3(2.0%) 2 1 1(1.4%) 2(7.7%) -
ARID1A 18(11.8%) 10 5 1 1 1 8(11.4%) 7(12.3%) 3(11.5%) 0.999
BAP1 11(7.2%) 7 1 3 10(14.3%) 1(3.8%) 0.0097
BRAF 3(1.9%) 3 3(4.3%) -
CDKN2A 2(1.3%) 1 1 1(1.4%) 1(3.8%) -
CTNNB1 2(1.3%) 1 1 2(3.5%) -
EGFR 2(1.3%) 2 1(1.7%) 1(3.8%) -
ERBB2 1(0.7%) 1 1(3.8%) -
ERBB4 1(0.7%) 1 1(1.4%) -
FBXW7 3(2.0%) 3 1(1.4%) 2(3.5%) -
FGFR3 2(1.3%) 1 1 2(2.8%) -
GNAS 1(0.7%) 1 1(1.7%) -
IDH1 11(7.2%) 11 11(15.7%) 0.0021
IDH2 3(2.0%) 3 3(4.3%) -
JAK3 1(0.7%) 1 1(1.7%) -
KDR 5(3.3%) 3 2 1(1.4%) 2(3.5%) 2(7.7%) -
KIT 2(1.3%) 2 1(3.5%) 1(3.8%) -
KRAS 43(28.1%) 43 11(15.7%) 7(47.4%) 5(19.2%) 0.0019
MET 1(0.7%) 1 1(3.8%) -
MLH1 1(0.7%) 1 1(1.7%) -
NRAS 6(3.9%) 6 5(9.3%) 1(1.7%) 0.421
PBRM1 14(9.2%) 8 5 1 10(14.3%) 2(3.5%) 2(7.7%) 0.182
PIK3CA 11(7.2%) 11 4(5.7%) 5(8.7%) 2(7.7%) 0.914
PIK3C2A 9(5.9%) 9 5(7.1%) 4(7.0%) 0.620
PIK3C2G 8(5.2%) 7 1 3(4.3%) 5(8.7%) 0.498
PTEN 4(2.6%) 4 1(1.4%) 2(3.5%) 1(3.8%) -
PTPN11 1(0.7%) 1 1(1.7%) 0(0.0%) -
RB1 1(0.7%) 1 1(3.8%) -
RET 10.7%) 1 1(1.7%) -
SMAD4 9(5.9%) 7 2 1(1.4%) 6(10.5%) 2(7.7%) 0.179
SMARCB1 2(1.3%) 2 0(0.0%) 2(7.7%) -
STK11 3(2.0%) 2 1 1(1.4%) 1(2.2%) 1(3.8%) -
TGFBR2 7(4.6%) 6 1 3(4.3%) 3(5.3%) 1(3.8%) 0.999
TP53 28(18.3%) 24 4 6(8.6%) 10(17.5%) 12(46.2%) 0.0019
Note: ICC, intrahepatic cholangiocarcinoma; ECC, extrahepatic cholangiocarcinoma; GBC, gallbladder carcinoma; 
M, missense mutation; N, nonsense mutation; Fs, frameshift mutation; D, deletion; S, splice site alteration. * Fisher's 
exact test corrected for multiple comparisons was calculated If ≥ 6 mutated cases were observed.
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Excluding ARID1A (12.3%), chromatin-remodeling genes 
were occasionally involved (PBRM1: 3.5%), whereas 
24.6% of ECCs showed mTOR pathway gene mutations, 
including PIK3CA (8.7%), PIK3C2A (7.0%), PIK3C2G 
(8.7%), and PTEN (3.5%). SMAD4 mutations were 
observed in 6 cases (10.5%) and were mutually exclusive 
to TGFBR2 mutations that were found in 3 cases (5.3%). 
Low prevalence mutations were found in CTNNB1, 
FBXW7, and KDR/VEGFR2. The EGFR T790M mutation 
was observed in one case [34].
GBC showed a high prevalence of TP53 mutations 
(12/26, 46.2%), and in 6 cases TP53 mutation was the only 
alteration detected. KRAS was mutated in 19.2% of cases. 
Chromatin remodeling genes were mutated in 30.8% 
of cases: ARID1A, 11.5%; BAP1, 3.8%; PBRM1, 7.7%; 
SMARCB1, 7.7%. MTOR pathway genes were mutated in 
11.5% of cases: PIK3CA (7.7%) and PTEN (3.8%).
mTOR pathway is dysregulated in all 
cholangiocarcinoma subtypes and Egfr is 
significantly overexpressed in intrahepatic 
cholangiocarcinomas
The results of immunohistochemistry are 
summarized in Table 3. We investigated mTOR pathway 
and Egfr expression in 113 neoplastic and 18 control 
cases. EGFR gene copy number was analyzed by FISH.
A significant over-expression of the activated 
forms of mTOR and its effectors p70S6K and 4EBP1 
was seen in most cancers with no significant differences 
among subtypes, but for p70S6K (Table 3). Of interest, 
the expression of phosphorylated ph-mTOR was 
significantly associated to the expression of the activated 
downstream effectors ph-4EBP1 and ph-p70S6K (p=0.05 
and p=0.00012, respectively). Pten was significantly 
Figure 1: Mutation and immunohistochemical landscape of 153 primary biliary carcinomas. The series includes 70 
intrahepatic cholangiocarcinomas (ICC), 57 extrahepatic cholangiocarcinomas (ECC), and 26 gallbladder carcinomas (GBC). Significantly 
mutated genes are listed vertically in decreasing order of prevalence of nonsilent mutation. Colored rectangles indicate mutation 
category observed in a given gene and tumour. Tumour classifications and molecular features are as indicated in the boxes on the right. 
Immunoistochemistry phenotypes and FISH analysis results are shown in the bottom tracks. White boxes indicate unknown status or 
missing data.
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Table 3: EGFR immunohistochemical and gene copy number status, and mTOR pathway 
immunohistochemical profiling.
Gene Total ICC ECC GBC P-value*
Im
m
un
oh
is
to
ch
em
is
tr
y
EGFR
0 37(32.7%)
17
(29.8%)
17
(42.5%)
3
(18.8%)
0.025
1 36(31.9%)
12
(21.0%)
16
(40.0%)
8
(50.0%)
2 25(22.1%)
15
(26.4%)
6
(15.0%)
4
(25.0%)
3 15(13.3%)
13
(22.8%)
1
(2.5%)
1
(6.2%)
PTEN
0 88(77.9%)
39
(68.4%)
34
(85.0%)
15
(93.8%) 0.085
1 25(22.1%)
18
(31.6%)
6
(15.0%)
1
(6.2%)
ph-mTOR
0 55(48.7%)
26
(45.6%)
21
(52.5%)
8
(50.0%)
0.785
1 58(51.3%)
31
 (54.4%)
19
(47.5%)
8
(50.0%)
ph-p70S6
0 45(39.8%)
29
(50.8%)
15
(37.5%)
1
(6.3%) 0.015
1 68(60.2%)
28
(49.2%)
25
(62.5%)
15
(93.7%)
ph-4EBP1
0 67(59.3%)
34
(59.6%)
25
(62.5%)
8
(50.0%) 0.785
1 46(40.7%)
23
 (40.4%)
15
(37.5%)
8
(50.0%)
FI
SH EGFR 
amplification 
6
(5.3%)
4
 (7.0%)
0
(0.0%)
2
(12.5%) 0.900
Note: ICC, intrahepatic cholangiocarcinoma; ECC, extrahepatic cholangiocarcinoma; GBC, 
gallbladder carcinoma.
*Fisher’s exact test corrected for multiple comparisons.
Figure 2: Representative examples of validation by Sanger sequencing of mutations identified using next generation 
sequencing. On the left of each sample is the representation of the results of next-generation sequencing where the reads are aligned to the 
reference genome as provided by the Integrative Genomics Viewer (IGV v.2.1, Broad Institute) software. On the right is the representation 
of the results of Sanger sequencing.
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Figure 3: Somatic mutations detected in chromatin 
remodeling genes ARID1A, BAP1, and PBRM1. 
Schematic representation of ARID1A, BAP1, and PBRM1 genes 
with the indication of the site of the somatic mutations identified 
in our study. Genomic coordinates are shown at the bottom 
track for each gene. Gray arrow indicates gene transcriptional 
direction. In black are represented the exons for each gene. 
Vertically, in correspondence of genomic location, bar chart 
indicate the type and number of mutations. Bar chart color is 
specific for mutation type: red, non synonymous coding;  green, 
deletion; blue, splice site; yellow, frameshift.
Figure 4: Immunohistochemical profiles of Egfr and mTOR pathway in cholangiocarcinomas. Representative examples 
of immunohistochemical staining in cholangiocarcinoma samples. The prevalence of positive cases within the different tumour types is 
shown. Original magnfications 20x.
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down-regulated in the whole series, particularly in ECC 
of common bile duct and in GBC: a weak cytoplasmic/
nuclear immunolabeling was observed in most cases.
Egfr expression was significantly altered in biliary 
tract tumours, with different subtype specific profiles. 
Forty cancers (35.4%) labeled for Egfr with sharp 
membranous pattern and signals ranging from very strong 
to moderate (Table 3, Figure 1 and Figure 4). Strong (3+) 
overexpression was observed only in the ICC subtype. 
At FISH analysis, 3/113 (2.7%) tumours showed EGFR 
amplification (Figure 1).
There was no significant association between 
both EGFR and mTOR pathway immunophenotype and 
mutational status.
TP53 mutation is an independent prognostic 
factor in cholangiocarcinoma
Survival data were available in 125 cases (ICC=51; 
ECC=50; GBC=24). Median survival was 31 months and 
79 (63.2%) subjects were followed to their deaths from 
disease.
At univariate analysis, the most significant predictors 
of cancer outcome were tumour stage (p=0.0001), TP53 
(p=0.0043) and KRAS (p=0.0162) mutations (Figure 5). 
Considering together KRAS/BRAF alterations, tumors 
characterized by mutations in KRAS/BRAF genes were 
associated to a worse patients’ prognosis (p=0.0054). 
ICC showed a better outcome than ECC (p=0.018). No 
correlation emerged for any of the other clinicopathologic 
variables considered: sex, age, grade, vascular/perineural 
invasion.
Cox multivariate analysis including tumour subtype, 
stage, grade, vascular and perineural invasion, IDH1/2 
mutations, KRAS and TP53 mutations, identified only 
Stage III (p=0.005; OR 4.27; 95%C.I. 1.54-11.8), Stage 
IV (p=0.003; OR 4.85; 95%C.I. 1.68-14.0), and TP53 
mutations (p=0.002; OR 2.26; 95%C.I. 1.35-3.78) as being 
significantly associated with cancer-related death (Table 
4). 
DISCUSSION
The results of our next-generation mutational survey 
of 56 cancer genes in 153 biliary tree carcinomas can be 
summarized as follows: i) the vast majority (77.1%) of 
Table 4: Multivariate survival analysis of 125 cholangiocarcinomas; median survival was 31 months 
and 79 subjects died of disease.
Variable Odds-ratio 95% C.I. P-value
Stage = I 1 - -
Stage = II 1.57 0.58-4.25 0.371
Stage = III 4.27 1.54-11.8 0.005
Stage = IV 4.85 1.68-14.0 0.003
Vascular invasion = yes 1.64 0.93-2.88 0.087
Perineural invasion = yes 0.63 0.36-1.08 0.093
TP53 = mutated 2.26 1.35-3.78 0.002
KRAS = mutated 1.51 0.91-2.51 0.110
Excluded variables
Grade = 1 1 - -
Grade = 2 1.38 0.57-3.37 0.474
Grade = 3 1.49 0.58-3.82 0.404
Class = ICC 1 - -
Class = ECC 1.31 0.70-2.41 0.390
Class = GBC 0.67 0.30-1.49 0.323
IDH1/2 = mutated 1.26 0.50-3.17 0.631
Note: ICC, intrahepatic cholangiocarcinoma; ECC, extrahepatic cholangiocarcinoma; GBC, gallbladder 
carcinoma.
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cancers harbours a driver-gene mutation; ii) the diverse 
sites of origin in the biliary tree have significantly different 
molecular profiles, and each site of origin also shows 
molecular heterogeneity; iii) targetable pathway alterations 
are present in 68% (104/153) of cancers, defining 
molecular cancer subclasses; iv) specific alterations are 
eligible for the investigational development of prognostic 
and non-invasive follow-up markers.
The vast majority of cancers (118/153, 77.1%) 
harboured at least one driver-gene mutation, and 39.2% 
(60/153 cases) showed concurrent mutations in two 
or more genes. KRAS was the most frequently mutated 
gene (28.1%), followed by TP53 (18.3%), as reported 
in prior studies [9, 14, 35-38]. The recently described 
frequent involvement of the chromatin remodeling genes 
ARID1A, PBRM1 and BAP1 [9, 13] was also confirmed 
in our series, being found in 11.8%, 9.2% and 7.2% of 
cases, respectively. Univariate survival analysis showed 
that KRAS mutations were associated to a worse patients’ 
prognosis confirming the univariate analysis previously 
described by Andersen [42]. Multivariate survival analysis 
identified tumour stage and TP53 gene mutations as 
independent predictors of poor survival.
The different sites of origin showed significantly 
diverse molecular characteristics. IDH1/IDH2 mutations 
were restricted to ICC (p=0.0005) and, with the exception 
of one GBC, BAP1 mutations were all found in ICC 
(p=0.0097). ECC and GBC were characterized by a high 
prevalence of KRAS (p=0.0019) and TP53 (p=0.0019) 
mutations, respectively.
The standard of care of biliary tract cancer is based 
on the combination of cisplatin and gemcitabine [39]. To 
date, clinical trials with targeted therapies for advanced 
biliary tract cancers have failed to produce significant 
benefits [11], and ongoing studies are exploring the 
combination of chemotherapy with novel MAPK/ERK 
Kinase (MEK) and mTOR inhibitors [40]. However, 
neither previous nor ongoing studies have considered 
evaluating tumour response against genetic alterations. 
Our identification of molecular subclasses with specific 
drug actionable pathway alterations in 104/153 (68.0%) 
tumours may tailor the design of trials based on the 
molecular selection of patients, irrespective of the site 
of origin, where actionable signaling pathways include 
tyrosine-kinase receptors (TKR), RAS/RAF/MAPK/ERK, 
mTOR, and TGF-ß.
Mutations in tyrosine kinase receptors (ALK, EGFR, 
ERBB2, ERBB4, FGFR3, MET, KIT, KDR/VEGFR2) 
potentially amenable to target therapies were found in 
9.2% of cases, with a higher prevalence in GBC (6/26 
cases, 23.1%) than in ICC (4/70 cases, 5.7%) and ECC 
(4/57, 7.0%). In spite of a relatively high prevalence of 
Egfr overexpression detected by immunohistochemistry 
(35.4% of cases with 2+ or 3+), only two cases had 
Figure 5: Overall survival according to pathological and mutational features. Overall survival of 125 cholangiocarcinomas 
is significantly affected by tumour stage (p=0.0001) (A), tumour location (p=0.0176) (B), TP53 (p=0.0043) (C) and KRAS (p=0.0162) (D) 
mutational status. Vertical axis indicates percent survival; horizontal axis shows time expressed in months. Kaplan–Meier and log-rank 
statistics were used to determine levels of significance.
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EGFR mutations and three had gene amplification, 
confirming the low prevalence reported in the literature 
in cholangiocarcinomas unassociated with chronic liver 
disease [14, 38, 41-44].
Mutations in components of the RAS pathway 
(KRAS, NRAS, BRAF) were observed in 34% of the whole 
series. In particular KRAS was the most frequently mutated 
gene in the 153 tumours (28.1%). KRAS mutations have 
been described in most of prior studies [9, 14, 35-38]. 
KRAS/NRAS/BRAF mutations were mutually exclusive, 
and the highest mutation prevalence in RAS pathway 
was observed in ECC (49.1%) vs. ICC (27.1%) and GBC 
(19.2%). Of note, RAS mutations sensitize tumours to 
MEK inhibitors, highlighting the importance of these 
mutations in the use of targeted therapies [11, 40].
MTOR pathway relevance in biliary tract cancers 
is suggested by our immunohistochemical detection of 
activated forms of mTor and its downstream effectors 
in 51.3% of the cancers. The molecular basis of this 
activation in a proportion of cases is the mutation in one 
of the genes involved in this pathway (i.e., AKT, FBXW7, 
PIK3CA, PIK3C2A, PIK3C2G, PTEN). This suggests 
that mTOR inhibitors might play a role in this molecular 
subgroup of patients.
TGF-ß/Smad signaling was altered in 16/153 cases 
(10.5%), 9 of which were ECC (9/57, 15.8%). Our finding 
supports previous studies demonstrating the involvement 
of this pathway in cholangiocarcinomas[45, 46]. Our 
study may have underestimated the involvement of this 
pathway, as only the mutational status of TGFBR2 and 
SMAD4 genes was investigated, and the latter is frequently 
inactivated by mechanisms different from intragenic 
mutations, such as homozygous deletions, which would 
not be detected by the techniques used in this study.
Alterations in chromatin remodeling genes 
(ARID1A, BAP1, IDH1, IDH2, PBRM1, SMARCB1) 
were found in 30.7% (47/153) of cancers in our series, 
confirming recent reports on the significant involvement 
of these genes in cholangiocarcinoma [9, 13]. Mutations 
in these genes appear to be either specific to ICC, as is 
the case of IDH1 and IDH2 (p=0.0005), or cluster within 
this cancer type as is the case for ARID1A, BAP1, and 
PBRM1 that were found in 34.3% (24/70) of ICC. The 
open challenge is now to translate knowledge of the 
targeting of these genes to improved patient care through 
either the development of new disease specific markers or 
of therapy targets. Of interest, IDH1/2 mutated cancers 
accumulate 2-hydroxyglutarate in tumour tissue and 
release the molecule in blood, and the measurement of 
2-hydroxyglutarate might be used as both a surrogate 
biomarker for IDH1/2 mutational status and a non-
invasive test for the assessment of tumour burden in ICC 
[47].
Our study is limited by the number of genes 
analyzed; 35 cancers (22.9%) showed no alterations in the 
56 genes assayed, including 50 genes from a commercial 
panel and a custom panel exploring 6 recently discovered 
cholangiocarcinoma genes [9, 13]. Mechanisms different 
from intragenic mutations, such as amplifications, 
deletions, translocations, and epigenetic anomalies should 
also be addressed.
In conclusion, we demonstrate that specific 
molecular alterations are associated to different 
cholangiocarcinomas categories and that potentially drug 
actionable pathways are evident in 68% of cases. These 
data further support the pathological and molecular 
heterogeneity characterizing biliary tree carcinomas. In 
currently designed clinical trials, cholangiocarcinomas 
are grouped together irrespective of their intrahepatic 
or extrahepatic site of origin. Our study shows that ICC 
and ECC should be considered separately, since they 
have different molecular characteristics. However, in the 
advent of molecular designed clinical trials, it would be 
appropriate to consider them together but only for the 
proportion of ICC and ECC sharing common molecular 
alterations. 
We also show that a high-throughput next-generation 
sequencing analysis can be successfully applied using low 
amounts of DNA from routinely processed paraffin tissues. 
Such a time- and cost-effective analysis is the basis to 
significantly improve the development of personalized 
treatments for cholangiocarcinoma patients, and their early 
access to innovative drugs.
MATERIALS AND METHODS
Cases
A retrospective series (1990-2011) of 153 surgically-
resected primary biliary cancers were retrieved from 
the FFPE archives of the ARC-Net Biobank at Verona 
University Hospital under the local ethics committee 
approval (n. prog. 1959). All cases were re-classified 
according to WHO 2010 [1], and included 70 ICC, 57 
ECC and 26 GBC. Staging was according to AJCC/
UICC 7th edition[26]. Matched normal liver was used to 
determine the somatic/germline nature of mutations.
In 113 cases (57 ICC, 40 ECC, 16 GBC), sufficient 
material for the construction of 1-mm cores tissue 
microarrays (TMAs) was available. Eighteen non-
neoplastic controls (8 normal biliary duct and 10 chronic 
cholecystitis) were included in the TMAs. Three tissue 
cores per case were analyzed.
DNA extraction and qualification
DNA was prepared after enrichment for neoplastic 
cellularity to at least 70% using manual microdissection 
of 10 consecutive 4-µm FFPE sections, purified using the 
QIAamp DNA FFPE Tissue Kit (Qiagen), and qualified as 
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reported elsewhere [24, 27].
Next-Generation Sequencing of Multiplex PCR 
Amplicons
Two multigene panels were used: the 50-gene Ion 
AmpliSeq Cancer Hotspot panel v2 (Life Technologies) 
and an AmpliSeq custom panel targeting 6 genes not 
included in the commercial panel. The first explores 
selected regions of 50 cancer- genes: ABL1, AKT1, ALK, 
APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, 
EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, 
FGFR2, FGFR3, FLT3, GNA11, GNAS, GNAQ, HNF1A, 
HRAS, IDH1, IDH2, JAK2, JAK3, KDR/VEGFR2, 
KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, 
NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, 
SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL. 
Details on target regions of the commercial panel are 
at http://www.lifetechnologies.com. The custom panel 
targets 6 genes selected upon the results of published ICC 
exome sequencing: ARID1A, BAP1, PBRM1, PIK3C2A, 
PIK3C2G, TGFBR2[13]. Details of the custom panel are 
in Supplementary Table 1.
Twenty nanograms of DNA were used for 
each multiplex PCR amplification. Emulsion PCR 
was performed with the OneTouch2 system (Life 
Technologies). The quality of the obtained libraries 
was evaluated by the Agilent 2100 Bioanalyzer on-chip 
electrophoresis (Agilent Technologies). Sequencing was 
run on the Ion Torrent Personal Genome Machine (PGM, 
Life Technologies) loaded with 316 (50-gene panel) or 318 
chips (6-gene panel). Data analysis, including alignment 
to the hg19 human reference genome and variant calling, 
was done using the Torrent Suite Software v.3.6 (Life 
Technologies). Filtered variants were annotated using the 
SnpEff software v.3.1. Alignments were visually verified 
with the Integrative Genomics Viewer; IGV v.2.2, Broad 
Institute.
DNA Sanger Sequencing
To validate the mutations detected by deep 
sequencing, BRAF (exon 11), KRAS (exon 2), and TP53 
(exons 2, 5, 6, 7, 8) were analyzed by Sanger sequencing 
[28].
Immunohistochemistry
The immunohistochemical expression of Egfr 
(Dako), Pten (Abnova Corporation), and of the 
phosphorylated forms of mTOR (Ser2448, clone 49F9; 
Cell Signaling) and its downstream effectors 4EBP1 
(Thr37/46, clone 236B4; Cell Signaling) and p70S6K 
(Thr389, clone 1A5; Cell Signaling) was examined on 
consecutive 4-µm FFPE TMA sections. Appropriate 
positive and negative controls were run concurrently.
Egfr expression was scored according to the EGFR 
pharmDx protocol (Dako): 0, no staining or membrane 
staining in ≤10% cancer cells; 1+, faint and partial 
membrane staining in >10% cancer cells; 2+, moderate 
and complete membrane staining in >10% cancer cells; 
3+, strong and complete membrane staining in >10% 
cancer cells. Cases were then classified in two groups 
Egfr-positive (2+ and 3+) or Egfr-negative (0 and 1+).
Pten expression was considered positive if more 
than 50% of neoplastic cells showed a moderate/strong 
nuclear and cytoplasmic immunoreaction[29].
Staining for phosphorylated markers (ph-mTOR, 
ph-4EBP1, and ph-p70S6K) was considered positive when 
tumour cells showed cytoplasmic and/or nuclear staining 
with equal to stronger intensity compared with that of 
endothelial cells [30].
Fluorescent in situ hybridization (FISH)
The EGFR gene copy number status was assessed 
applying the Vysis EGFR/CEP7 Probe Kit (Vysis/Abbott 
Molecular). At least 50 representative nuclei per specimen 
were scored and EGFR-amplification was defined as 
described [31].
Statistical analysis
Kruskal-Wallis test, Chi-squared test with Monte 
Carlo simulation, and Fisher’s exact test corrected for 
multiple comparisons were used as appropriate. For 
comparison of Kaplan-Meier survival curves, Mantel-Cox 
log-rank test was used; for multivariate survival analysis, 
stepwise Cox proportional hazards regression was used; 
selection of the best model was performed using the 
“backward elimination” algorithm. For all the analyses 
a p-value below 0.05 was considered significant. Graphs 
and univariate analyses were performed using GraphPad 
Prism® version 5.00 for Mac (GraphPad Software, San 
Diego California USA), multivariate Cox regression was 
done with R v. 3.0.2, using survival library v.2.37-4.
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